T he prevalence of the metabolic syndrome among developed countries is rising, and this is largely driven by increasing obesity rates. Central obesity plays a key role in the pathogenesis of the metabolic syndrome: it promotes inflammation, hypertension and dyslipidaemia, and leads to the development of type 2 diabetes mellitus and atherosclerosis. Clinical management should be focused on multifactorial intervention to address all the associated cardiovascular risk factors. The atherogenic mixed dyslipidaemic profile associated with the metabolic syndrome is an important target for intervention to reduce the risk of type 2 diabetes and premature cardiovascular disease. Diabetes Vasc Dis Res 2007;4(suppl 3):S2-S4
Introduction
The metabolic syndrome is characterised by a cluster of metabolic disorders that increase the risk of type 2 diabetes mellitus and cardiovascular disease. The condition is now highly prevalent in both developed and developing countries. Data from the Third National Health and Nutrition Examination Survey (NHANES III) on 8,814 men and women in the US who were followed up from 1988 to 1994 suggested that about 20-30% of adults in developed countries have the metabolic syndrome. 1 Its prevalence increases markedly among older people: in those aged 60 years or more, nearly 50% of people are estimated to have the metabolic syndrome (figure 1). 1 It is likely that the current prevalence is even higher, given the unrelenting increase in obesity rates. 2 Obesity drives the sequelae of metabolic syndrome Although the metabolic syndrome is defined in various ways, central obesity, dyslipidaemia, impaired glucose tolerance and hypertension are crucial features (table 1) . 3 These criteria are also consistent with evidence from the INTERHEART study, a global case-control study which identified dyslipidaemia (reported as the ratio of apolipoproteins B/A, a measure of the ratio of atherogenic to atheroprotective lipoproteins), hypertension, abdominal obesity and diabetes among the main nine risk factors that collectively account for 90% of the population-attributable risk for myocardial infarction (MI). 4 Adipose tissue plays a vital role in the pathogenesis of the . 5, 6 Abdominal fat associated with central obesity, a characteristic feature of the metabolic syndrome, is a major source of the excessive flux of free fatty acids, which are known to have pro-arrhythmic properties. Prolonged release of free fatty acids is implicated in the development of type 2 diabetes since it promotes insulin resistance and the associated loss of pancreatic beta-cell function. 7 Abdominal obesity is an important predictor of adverse clinical outcomes, such as sudden death. In the Paris Prospective Study I, conducted in 7,079 asymptomatic men aged 43 to 52 years who did not have ischaemic heart disease at baseline, the greater the sagittal abdominal diameter (a measure of abdominal obesity), the greater the risk of sudden death. This association was independent of body mass index and known cardiovascular risk factors. 8
Metabolic syndrome increases cardiovascular risk
There is extensive evidence showing that the presence of the metabolic syndrome increases the risk of both cardiovascular and all-cause mortality. In the Botnia study, involving 4,483 subjects with normal glucose tolerance, impaired glucose tolerance or type 2 diabetes who were followed up for a median of 6.9 years, evidence of the metabolic syndrome trebled the risk for coronary heart disease (CHD) and stroke. 9 Additionally, in the Kuopio Ischaemic Heart Disease Risk Factor Study, a population-based prospective cohort study in 1,209 Finnish men aged 42-60 years without cardiovascular disease or diabetes at baseline, the presence of the metabolic syndrome increased the risk of CHD more than fourfold and doubled all-cause mortality. Individuals who had a greater number of features of the metabolic syndrome were at greater risk. 10 This association is also evident in non-Caucasian individuals. In the Tanno and Sobetsu Study of 808 Japanese men without hypertension, dyslipidaemia or diabetes at baseline, the incidence of cardiac disease over a six-year follow-up period was about 2-fold higher in men with at least three features of the metabolic syndrome (about 25% of the study population) than in those with no features of metabolic syndrome (11.7% vs. 6.7%). 11 Furthermore, as shown by data from the San Antonio Heart Study, the presence of both diabetes and metabolic syndrome accentuates cardiovascular risk, particularly in women ( figure 3 ). 12 
Importance of dyslipidaemia
The increased risk of cardiovascular disease associated with the metabolic syndrome has many causes (figure 4) but dyslipidaemia plays a prominent role. Both the metabolic syndrome and type 2 diabetes are commonly associated with an abnormal lipoprotein phenotype characterised by elevated triglycerides, a low level of high-density lipoprotein cholesterol (HDL-C), and an accumulation of small, dense lowdensity lipoprotein (LDL) particles (the so-called atherogenic dyslipidaemic phenotype). Notably, levels of LDL-C are often normal. 13 In an analysis of data from the United Kingdom Prospective Diabetes Study, abnormal lipids were CLINICAL IMPLICATIONS identified as the strongest risk factors for CHD in type 2 diabetes, 14 particularly among women. 15 Low HDL-C (< 1.04 mmol/L) and elevated triglycerides (> 1.7 mmol/L) levels are clearly established as markers of increased cardiovascular risk, as recognised by current treatment guidelines. 16, 17 Recent data from the Quebec Cardiovascular Study also show that the presence of small, dense LDL particles is associated with an increased risk of ischaemic heart disease. 18 This LDL phenotype is also implicated in the development of type 2 diabetes per se. 19 Management of metabolic syndrome has two main objectives, therefore. First, clinicians should try to reduce the underlying causes of the syndrome, by lifestyle intervention strategies aimed at reducing weight and increasing physical activity. In addition to global management of cardiovascular risk, most patients will also require pharmacological therapy. Given the importance of the associated atherogenic dyslipidaemic profile, it is clear that lipid-modifying strategies have a prominent role in the management of metabolic syndrome and type 2 diabetes to prevent premature cardiovascular disease.
Conclusion
The increasing prevalence of the metabolic syndrome, driven by escalating obesity rates, warrants urgent action. Multifactorial intervention is crucial in the prevention of type 2 diabetes and the reduction of global cardiovascular risk. Of the associated risk factors, the atherogenic dyslipidaemic profile characteristic of this syndrome is a key target. Lipidmodifying strategies have an important role therefore in clinical management of the metabolic syndrome.
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